The most effective and safe contraceptive method, intrauterine devices (IUDs), is still underutilized due to the pain barrier during IUD insertion. Lidocaine, a well-known local anesthetic, can be used to relieve IUD insertion pain. This study aimed at formulation, in vitro, in vivo and clinical evaluation of a novel lidocaine dual-responsive in situ gel. Pluronic and Gelrite were used as thermosenstive and ion-activated polymers, respectively. In situ gels containing 2% lidocaine, pluronics and/or Gelrite were prepared. The optimized dual-responsive formula (F) was clear, with 95% drug content, free flowing at room temperature and gel at vaginal temperature (T of 28 °C). This optimized dual-responsive in situ gel was found to be superior to single-responsive one due to presence of Gelrite, imparting resistance to dilution effect of simulated vaginal fluids. DSC thermograms revealed no interaction between formulation components. Biocompatibility study showed no degeneration, necrosis or inflammation. Optimized dual-responsive in situ gel was further evaluated for pain reduction efficiency via a pilot randomized, double-blinded, placebo-controlled clinical trial showing ease of self-administeration by patients and significant pain reduction induced at all steps of IUD insertion. In conclusion, lidocaine dual-responsive in situ gel can be effectively used in prevention of pain during IUD insertion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijpharm.2018.01.033 | DOI Listing |
Soft Matter
January 2025
Research Center for Macromolecules & Biomaterials, National Institute for Materials Science, 1-2-1 Sengen, Tsukuba 305-0047, Japan.
We developed a facile one-pot method for fabricating physical gels consisting of ultrahigh molecular weight (UHMW) polymers and highly concentrated lithium salt electrolytes. We previously reported physical gels formed from the entanglement of UHMW polymers by radical polymerisation in aprotic ionic liquids. In this study, we found that the molecular weight of methacrylate polymers formed by radical polymerisation increased with the concentration of lithium salts in the organic solvents.
View Article and Find Full Text PDFAdv Healthc Mater
January 2025
Laboratory for Biointerfaces, Empa, Swiss Federal Laboratories for Materials and Technology, Lerchenfeldstrasse 5, St. Gallen, 9014, Switzerland.
Surface-mediated transmission of pathogens plays a key role in healthcare-associated infections. However, proper techniques for its quantitative analysis are lacking, making it challenging to develop novel antimicrobial and anti-fouling surfaces to reduce pathogen spread via environmental surfaces. This study demonstrates a gelatin hydrogel-based touch transfer test, the HydroTouch test, to evaluate pathogen transmission on high-touch surfaces under semi-dry conditions.
View Article and Find Full Text PDFJPRAS Open
March 2025
Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Background: Breast cancer patients experience acute radiation dermatitis (ARD) during radiation therapy (RT). This study investigated the prophylactic effect of a newly developed xenogeneic platelet-rich plasma (PRP) lotion on ARD for breast cancer patients.
Methods: This study enrolled patients with ductal carcinoma in situ and early-stage invasive breast cancers after breast-conserving surgery.
Bioact Mater
April 2025
School of Medicine South China University of Technology, Guangzhou, Guangdong, 510006, China.
The cardiac microenvironment profoundly restricts the efficacy of myocardial regeneration tactics for the treatment of myocardial infarction (MI). A prospective approach for MI therapeutics encompasses the combined strategy of scavenging reactive oxygen species (ROS) to alleviate oxidative stress injury and facilitating macrophage polarization towards the regenerative M2 phenotype. In this investigation, we fabricated a ROS-sensitive hydrogel engineered to deliver our previously engineered IL-1β-VHH for myocardial restoration.
View Article and Find Full Text PDFCurr Drug Deliv
January 2025
Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
Due to the blood-brain barrier (BBB) and issues with oral and other traditional routes of administration, psychiatric disorders present significant challenges in getting therapeutics into the brain. The nose-to-brain pathway, also known as intranasal delivery, has shown promise in overcoming these barriers since it targets the brain directly and bypasses the BBB. This review explores nanocarriers' potential for intranasal delivery of therapeutics in the treatment of psychiatric disorders.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!